---
document_datetime: 2023-09-21 19:10:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/pritor-epar-procedural-steps-taken-authorisation_en.pdf
document_name: pritor-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3644202
conversion_datetime: 2025-12-23 06:34:07.219093
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Glaxo  Group  Ltd,  United  Kingdom  submitted  on  9  October  1997  to  the  European Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  an  application  for  the  marketing authorisation of the medicinal product Pritor falling within the scope of Part B of the Annex of the Council Regulation (EEC) 2309/93, of the 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP  were:

Rapporteur:

Prof. S. Garattini

## Licensing status

Telmisartan was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 27 October 1997.
- The Rapporteur's assessment report was circulated to all CPMP Members on 19 January 1998. The  Co-rapporteur's  assessment  report  was  circulated  to  all  CPMP  Members  on  19  January 1998.
- The CPMP consolidated list of questions was adopted on 23 February 1998.
- The responses to CPMP the consolidated list of questions was received on 21 April 1998
- The joint Rapporteur-Co-Rapporteur assessment report on the responses  to  the  CPMP consolidated list of questions was circulated on 26 May 1998.
- During its June 1998 meeting, the CPMP discussed and adopted a list of issues to be addressed by the company during a hearing.
- The evaluation clock was stopped on 23 June 1998.
- The  company  submitted  additional  information  regarding  outstanding  points  for  clarification regarding quality aspects on 30 June 1998.
- An addendum to the joint Rapporteur-Co-Rapporteur assessment report was received on 7 July 1998.
- A hearing was held at the CPMP meeting on 21 July 1998, to address the remaining outstanding issues.
- The CPMP, during its meeting on 21-23 July 1998, considered the responses provided by the company and discussed the recommendations presented by the Rapporteur. Amendments to the Summary of Product Characteristics were discussed.
- During the meeting on 21-23 July 1998 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation for Pritor on 23 July 1998 .
- The  European  Commission  issued  on  11  December  1998,  a  Marketing  Authorisation  valid throughout the European Union.

Co-Rapporteur:

Prof. A. Hildebrandt